Data from our study and previous reports suggest that increased tumor infiltration of neutrophils induced by cabozantinib might be due to the increased neutrophil-related chemokines CCL11 and CXCL12 in the tumor microenvironment. The gene discussed is CXCL12; the disease is neoplasm.